Table 1 Changes in body weight in active drug treatment versus placebo (lifestyle modification alone) groups in selected recent obesity drug trials.
From: Structured lifestyle modification as an adjunct to obesity pharmacotherapy: there is much to learn
Trial Name | Author/ year (reference) | Medication and Dose | Trial Duration (Weeks) | Lifestyle Intervention Features | Number of Participants | Weight Loss with Active Drug Treatment (%) | Weight Loss with Lifestyle Intervention Alone (%) |
|---|---|---|---|---|---|---|---|
LEADER | Marso/ 2013 [38] | Liraglutide 1.8 mg | 60 | The importance of lifestyle approaches for diabetes management including dietary changes, physical activity and weight management was stressed to all participants. | 9340 | 5.8% | 3.3% |
SCALE | Pi-Sunyer/ 2015 [31] | Liraglutide 3.0 mg | 56 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 3731 | 8% | 2.6% |
MODEL | Wadden/ 2018 [70] | Liraglutide 3.0 mg | 52 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. A second arm received a 1200 kcal, 12-week meal replacement diet programme. | 150 | 11.5% | 6.1% |
STEP1 | Wilding/ 2021 [2] | Semaglutide 2.4 mg | 68 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 1961 | 14.9% | 2.4% |
STEP 2 | Davies/ 2021 [43] | Semaglutide 1 and 2.4 mg | 68 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 1210 | 6.9 and 9.6% | 3.4% |
STEP 3 | Wadden/ 2021 [46] | Semaglutide 2.4 mg | 68 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. A second arm received a 1000-1200 kcal, 8-week meal replacement diet programme, followed by a hypocaloric (1200-1800 kcal) diet for 68 weeks, and with 100 minutes of physical activity per week increasing to 200 minutes per week gradually by 16 weeks. | 567 | 16% | 5.7% |
STEP 4 | Rubino/ 2022 [48] | Semaglutide 2.4 mg | 75 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 902 | 18% | 5% |
STEP 5 | Garvey/ 2021 [45] | Semaglutide 2.4 mg | 68 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 304 | 15.2% | 2.6% |
STEP 6 | Kadowaki/ 2022 [47] | Semaglutide 1.7 and 2.4 mg | 68 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 401 | 9.6 and 13.2% | 2.1% |
STEP 8 | Rubino/ 2022 [48] | Semaglutide 2.4 mg | 68 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 338 | 15.8% | 6.4% |
SURMOUNT 1 | Jastreboff/ 2022 [3] | Tirzepitide 5, 10 and 15 mg | 72 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 2539 | 15, 19.5 and 20.9% | 3.1% |
SURMOUNT 2 | Garvey/ 2023 [71] | Tirzepitide 10 and 15 mg | 72 | Dietary intervention seeking a 500 kcal/ day deficit, as well as a target of 150 minutes of physical activity per week. | 1514 | 12.8 and 14.7% | 3.2% |
Retatrutide | Rosenstock/ 2023 [54] | Retatrutide 12 mg | 36 | None (Phase 2 trial) | 281 | 16.9% | 2% |
Retatrutide | Jastreboff/ 2023 [4] | Retatrutide 12 mg | 48 | None (Phase 2 trial) | 338 | 24.2% | 2.1% |
